Published in Drug Week, June 13th, 2008
"Since many B-cell malignancies express the CD22 antigen on their cell surface, CAT-3888 is intended to treat patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2008-06-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.